Jason Wallach
Jason Wallach | |
|---|---|
| Born | 1987 (age 38–39) |
| Education | Indiana University of Pennsylvania; University of the Sciences |
| Occupations | Pharmacologist; Assistant professor |
| Years active | 2009–present |
| Employer(s) | Saint Joseph's University; Philadelphia College of Pharmacy |
| Website | https://directory.sju.edu/jason-wallach https://www.wallachlab.com/ |
Jason Wallach (born 1987) is an American pharmacologist who studies psychedelic drugs and other hallucinogens. He is an assistant professor at Saint Joseph's University's Philadelphia College of Pharmacy.
In August 2020, Wallach began a partnership with the pharmaceutical company Compass Pathways for his research lab to develop novel psychedelic drugs as therapeutics. Hamilton Morris, a psychedelic journalist and the host of Hamilton's Pharmacopeia, works as a chemist in Wallach's lab.
Wallach graduated from Indiana University of Pennsylvania with his bachelor's degree in cell and molecular biology in 2008 and graduated with his Doctor of Philosophy degree in pharmacology and toxicology from the University of the Sciences in 2014.
In 2023, Wallach, Morris, and other colleagues published a key paper characterizing the serotonin 5-HT2A receptor intracellular signaling cascades mediating the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. Wallach and Morris have intensively studied the auditory psychedelic diisopropyltryptamine (DiPT) for more than a decade.
See also
References
- 1 2 3 4 5 Wood, Sam (15 February 2021). "Envisioning a psychedelic future for Philadelphia's USciences as it pairs with Compass Pathways for a Drug Discovery Center". inquirer.com. Retrieved 28 January 2025.
{{cite web}}: CS1 maint: deprecated archival service (link) - 1 2 3 4 5 Ben Seal (May 2024). "A Psychedelic Renaissance". Saint Joseph's University Magazine. Retrieved 28 January 2025.
- ↑ Wallach JV (January 2009). "Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception". Med Hypotheses. 72 (1): 91–4. doi:10.1016/j.mehy.2008.07.052. PMID 18805646.
- ↑ Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Test Anal. 6 (7–8): 614–632. doi:10.1002/dta.1620. PMID 24678061.
- 1 2 3 Semley, John (26 July 2022). "The High-Stakes Race to Engineer New Psychedelic Drugs". WIRED. Archived from the original on 27 December 2024. Retrieved 28 January 2025.
- 1 2 "Psychedelic Compounds are Focus of USciences Lab". Newsroom. 18 October 2021. Retrieved 9 January 2025.
- ↑ "Jason V Wallach". University Directory. Retrieved 28 January 2025.
- ↑ Lomte, Tarun Sai (19 December 2023). "Scientists design non-hallucinogenic psychedelic treatments potentially accelerating research on mental health benefits". News-Medical. Retrieved 28 January 2025.
- ↑ "Trip or treat?". EurekAlert!. 15 December 2023. Retrieved 28 January 2025.
- ↑ Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nat Commun. 14 (1): 8221. doi:10.1038/s41467-023-44016-1. PMC 10724237. PMID 38102107.
- ↑ Ferriss, Tim (24 September 2018). "The Tim Ferriss Show Transcripts: Hamilton Morris (#337)". The Blog of Author Tim Ferriss. Retrieved 17 August 2026.
But I've had the opportunity to try a number of different DMT derivatives, MET, MPT, DPT, DIPT, and so on, and IPT and a number of others. [...] Right now, I'm working with a chemist named Jason Wallach. And we are trying to do a process called autoradiography where you take a radiolabeled drug, and you look at the distribution in the brain. And we're looking specifically at a drug that seems to distort the way sound is perceived based on Shulgin's reports. And we want to see, with the radiolabeled drug, how it will distribute in a rodent's brain. So we're trying to raise a little bit of money to do that sort of research. It's not all that expensive. And it could really have interesting bearing on our understanding of auditory perception.
- ↑ Hurst A, Bajo VM (2026). "N,N-Diisopropyltryptamine and diptogenia: proposed mechanisms for a frequency-selective pitch-distorting psychedelic". Brain Commun. 8 (2) fcag093. doi:10.1093/braincomms/fcag093. PMC 13069925. PMID 41971051.
Acknowledgements: With special thanks to Jason Wallach, Hamilton Morris, and Jitka Nykodemova for their passion and expertise on the topic.
- ↑ Hamilton Morris (28 July 2022). "POD 53: The inside story of the DEA battle with lawyers John Hunter and Matt Zorn". The Hamilton Morris Podcast (Podcast). John Hunter (guest), Matt Zorn (guest). Patreon. Event occurs at 0:46–2:43. Retrieved 16 August 2026.
So for anyone listening to this who's followed my work for a while I'm often asked some variation of a question like what is your favorite drug or what is the most interesting drug in the world to you. And I always say oh I don't know, you know, I can't answer [...] but the answer was DiPT. I didn't ever say DiPT because I was afraid that if I drew any attention to it that I would raise its profile in some way and the result would be DiPT being prohibited. And the reason that I cared about DiPT so much was not because it's my favorite drug in the sense that I enjoy it recreationally. The reason is that I've spent about 13 years studying DiPT with Jason and none of this research has been published. This has been an extremely labor-intensive ongoing labor of love that we have done with no external funding for countless hours [...]
- ↑ John T. Hunter (7 July 2022). Jason Wallach and Hamilton Morris' Amended Supplemental Prehearing Statement (PDF) (Report). U.S. Department of Justice, Drug Enforcement Administration. 22-15. Retrieved 17 August 2026.
Mr. Morris will testify that he is a journalist, documentarian, and medicinal chemist working at Saint Joseph's University in Philadelphia. Mr. Morris has been studying the history, chemistry and pharmacology of DiPT with Dr. Wallach for 13 years. During this time they have synthesized and pharmacologically evaluated a number of DiPT structural analogs with the hope of identifying DiPT's mechanism of action. He qualifies as an expert in the field of chemistry, and will further testify as a fact witness to provide a summary of the medical and scientific literature presently known on the subject of DiPT. [...]
